Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3774 - Impact of Prognostic Factors and Risk Groups on Overall Survival (OS) in Patients Treated With Pembrolizumab vs Investigator’s Choice Chemotherapy for advanced Urothelial Cancer (UC): Post Hoc Analysis of KEYNOTE-046

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Tumour Site

Urothelial Cancers

Presenters

Joaquim Bellmunt

Citation

Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283

Authors

J. Bellmunt1, R. de Wit2, D.J. Vaughn3, Y. Fradet4, J.L. Lee5, L. Fong6, N.J. Vogelzang7, M.A. Climent8, D. Petrylak9, T.K. Choueiri10, A. Necchi11, W.R. Gerritsen12, H. Gurney13, D.I. Quinn14, S. Culine15, C.N. Sternberg16, E. Jensen17, T. Frenkl18, R.F. Perini17, D. Bajorin19

Author affiliations

  • 1 Medical Oncology, IMIM-Hospital del Mar Medical Research Institute, 08003 - Barcelona/ES
  • 2 Medical Oncology, Erasmus MC Cancer Institute, 3015 CE - Rotterdam/NL
  • 3 Medical Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia/US
  • 4 Medical Oncology, CHU de Québec-Université Laval, Québec City/CA
  • 5 Medical Oncology, Asan Medical Center and University of Ulsan College of Medicine, Seoul/KR
  • 6 Medicine, University of California, San Francisco, 94143 - San Francisco/US
  • 7 Medical Oncology, Comprehensive Cancer Centers of Nevada, 89169 - Las Vegas/US
  • 8 Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia/ES
  • 9 Medical Oncology, Smilow Cancer Hospital at Yale University, 06520-8032 - New Haven/US
  • 10 Medical Oncology, Dana-Farber Cancer Institute, Boston/US
  • 11 Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 12 Medical Oncology, Radboud University Medical Center, 6500 HB - Nijmegen/NL
  • 13 Medical Oncology, Westmead Hospital and Macquarie University, 2109 - Macquarie Park/AU
  • 14 Medical Oncology, University of Southern California Norris Comprehensive Cancer Center and Hospital, 90033 - Los Angeles/US
  • 15 Medical Oncology, Hôpital Saint-Louis, 75010 - Paris/FR
  • 16 Medical Oncology, San Camillo Forlanini Hospital, 00152 - Rome/IT
  • 17 Medical Oncology, Merck & Co., Inc., Kenilworth/US
  • 18 Medical Oncology, Merck & Co., Inc., 07033 - Kenilworth/US
  • 19 Medical Oncology, Memorial Sloan Kettering Cancer Center, 10022 - New York/US
More

Resources

Abstract 3774

Background

Well-defined prognostic factors (PF) and risk groups have been shown to impact OS in first- and second-line chemotherapy (chemo) for UC. Post hoc analysis of survival outcome per level of risk was conducted using data from the phase 3 KEYNOTE-045 trial (NCT02256436).

Methods

Data from the Oct 26, 2017 data cut were included. The presence or absence of 4 predefined criteria applied at study randomization was noted for each patient: ECOG PS (0 vs 1 or 2), hemoglobin level (<10 g/dL vs ≥ 10 g/dL), liver metastases (yes vs no), and time from prior chemotherapy (<3 months vs ≥ 3 months). Patients were grouped per the number of PFs they had (0, 1, 2, or 3/4), and OS was estimated for each risk group receiving pembrolizumab (pembro) or chemo, using Kaplan-Meier (K-M) statistics.

Results

Data from 529/542 patients were included. Stratified randomization ensured that the distribution of risk levels was similar between the 2 treatment arms. Overall, OS decreased with increasing numbers of PFs for pembro (from 19 to 5 months) and chemo (from 18 to 3 months) (Table). Within the chemo arm, the results of the K-M survival profiles were consistent with previously published data, in which each risk group had different outcomes. Within the pembro arm, outcomes of pts with 0 and 1 PF were distinct from those with 2 and 3/4 PF groups. OS was longer with pembro than with chemo across all PF subgroups.Table: 901P

0 PFS1 PF2 PFs3 or 4 PFs
OSPembro n = 54Chemo n = 45Pembro n = 97Chemo n = 97Pembro n = 66Chemo n = 80Pembro n = 45Chemo n = 45
Median (95% CI),months18.5 (14.1-NE)17.6 (10.2-24.2)12.6 (8.1-18.9)8.8 (7.4-11.2)5.1 (2.8-8.7)4.7 (3.5-6.1)4.6 (2.3-7.4)3.4 (2.4-4.6)
24-month OS, %41.436.735.317.812.65.613.7NR
30-month OS, %41.431.625.913.7NR5.611.4NR
HR for OS0.81 (0.49-1.36)0.67 (0.48-0.93)0.82 (0.57-1.16)0.61 (0.39-0.97)

Conclusions

OS within the pembro and chemo arms decreased with increasing numbers of PFs. OS of patients treated with pembro was longer than those receiving chemo across the risk groups. Patients treated with pembro who had 2 or 3/4 PFs had overall similar outcomes. Additional analyses are needed to characterize novel risk models for patients treated with immunotherapies.

Clinical trial identification

NCT02256436, trial initiation date: October 3, 2014.

Legal entity responsible for the study

Merck & Co., Inc.

Funding

Merck & Co., Inc.

Editorial Acknowledgement

Medical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

J. Bellmunt: Consultant/advisory: Pierre Fabre, Astellas, Pfizer, Merck, Genentech, Novartis, AstraZeneca, BMS; Travel: Pfizer, MSD Oncology; Research funding: Millennium, Sanofi. R. de Wit: Consultant/advisory: Sanofi, Merck, Lilly, Roche/Genentech; Honoraria: Sanofi, Lilly, Roche/Genentech, Merck; Research funding: Sanofi. D.J. Vaughn: Research funding: Merck, Roche, Genentech. Y. Fradet: Consultant/Advisory: Merck, Astellas, Roche, AstraZeneca; Research funding: Astellas; Travel: Roche. J.L. Lee: Consultant/Advisory: Astellas, AstraZeneca, Eisai; Honoraria: Pfizer, Astellas, Novartis, BMS; Research funding: Pfizer, Janssen, Novartis, Exelixis, BMS, Roche/Genentech. L. Fong: Consultant/Advisory: Atreca, Ideava Biosciences, MIODx; Research funding: BMS, Abbvie, Roche/Genentech, Janssen, Merck, Nektar. N.J. Vogelzang: Consultant/Advisory: Amgen, Pfizer, Bayer, Genentech/Roche, AstraZeneca, Caris Life Science, Tolero; Speakers’ bureau: Bayer, Sanofi, BMS, Exelixis, AstraZeneca, Stock, Caris Life Sciences, Honoraria: Pfizer; Research funding: Endocyte, Merck. M.A. Climent: Honoraria: Roche, BMC, Bayer, Astella, Sanofi, Pfizer, Novartis; Consulting/Advisory: Janssen, Pfizer, Roche, Sanofi, Astellas Pharma, Bayer; Travel: Astellas, Janssen, Pfizer. D. Petrylak: Consultant/Advisory: Bayer, Johnson & Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche, Sanofi; Research funding: Johnson & Johnson, Sanofi, Endocyte, Genentech, Merck, Astellas, Novartis, AstraZeneca, Bayer, Lilly, Seattle Genetics. T.K. Choueiri: Consultant: Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck, BMS Roche/Genentech, Eisai, AstraZeneca, Exelixis, Alligent; Honoraria: NCCN; Research funding: Pfizer, Novartis, Merck, Exelixis, GlaxoSmithKline, BMS, AstraZeneca, Roche/Genentech, Celldex. W.R. Gerritsen: Consultant/Advisory: BMS, Amgen, Merck, Aglaia Biomedical Ventures, Astellas, Bayer, Janssen-Cilag; Speakers’ bureau: Astellas, Bayer, Janssen-Cilag; Travel: Amgen, Bayer. H. Gurney: Consultant/Advisory: BMS, Ipsen, Merck, AstaZeneca; Travel: Astellas, Sanofi; Honoraria: Roche, Astellas; Research funding: Pfizer. D.I. Quinn: Consultant/Advisory: Astellas, Pfizer, BMS, Genetech/Roche, Merck, Bayer, Exelixis, AstraZeneca, Sanofi; Honoraria: Bayer, Astellas, Pfizer, Genentech/Roche, Merck, BMS, AstraZeneca, Sanofi, Millennium, Genentech/Roche, GlaxoSmithKline. S. Culine: Consultant/Advisory: Roche, Janssen; Speakers bureau: Astellas, Roche, Merck; Travel: Amgen, Astellas, Janssen. C.N. Sternberg: Honararia: OncoGenex, Lilly, Janssen, Merck, BMS, AstraZeneca, Roche/Genentech; Research funding: Lilly, Janssen, Merck, BMS, AstraZeneca, Roche/Genentech. E. Jensen: Employment: Merck. T. Frenkl, R.F. Perini: Employment and stock. D. Bajorin: BMS, Novartis, Roche/Genentech, Merck, Lilly, Fidia Farmaceutici, Urogen Pharma, Lilly Pfizer, EMD Serono; Honoraria: Merck; Research funding: Dendreon, Novartis, Amgen. Genentech/Roche, Merck, BMS. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.